FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	DC	20549
vasilligton,	D.O.	20070

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APP	OMB APPROVAL								
OMB Number:	3235-0287								
Estimated average burden									
hours per response	: 0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* ELMS STEVE				<u>A</u>	2. Issuer Name and Ticker or Trading Symbol ADMA BIOLOGICS, INC. [ADMA] 3. Date of Earliest Transaction (Month/Day/Year)								Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title Other (specify						
(Last)	(F	rst)	(Middle)		02/26/2024									below)			below)	specify	
888 SEV 12TH FL	ENTH AVI OOR	3			4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person					
(Street) NEW YO	ORK N	Y	10106											Form filed by More than One Reporting Person					
(City)	(S	tate)	(Zip)		- Ri	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a capacity satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instru													
		Tab	le I - No	n-Deri	vativ	e Sec	curities	s Ac	quired,	, Dis	posed o	f, or Be	neficiall	y Owned					
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)				Execution Date,		3. Transaction Code (Instr. 8) 4. Securities Acquired (Disposed Of (D) (Instr. 5)					Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of ndirect Beneficial Dwnership Instr. 4)						
								Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)			[
Common Stock 02/26/2					6/2024	2024		A		24,040 ⁽¹⁾ A		\$0	76,4	5,441 ⁽²⁾		D			
Common Stock												3,615,671				See Cootnote ⁽³⁾			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security (Instr. 3) 3. Transaction Date (Month/Day/Year) if any (Month/Day)			Date,	4. Transaction Code (Instr. 8)		n of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)			
			Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amount or Number of Shares								
Stock Option (right to buy)	\$5.4	02/26/2024			A		37,541		(4)		03/26/2034	Common Stock	37,541	\$0	37,54	41	D		

Explanation of Responses:

- 1. These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date.
- 2. Includes, as of the transaction date, (i) 24,040 RSUs granted on February 26, 2024 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 25,815 RSUs granted on March 6, 2023, which will vest in full on March 6, 2024; and (iii) 26,586 shares of common stock owned by the reporting person.
- 3. These shares are owned by Aisling Capital II LP ("Aisling"). Mr. Elms is Aisling's designee for nomination to the Board. As a Managing Member of Aisling Capital Partners, LLC ("Aisling Partners"), a control person of Aisling, and as a member of the investment committee of Aisling Capital Partners, LP ("Aisling GP"), Mr. Elms may be deemed to be the beneficial owner of shares of common stock owned of record by Aisling. Mr. Elms disclaims beneficial ownership of Aisling's investment in the Company and Aisling Partners' ownership of the Company's options, except to the extent of his pecuniary interest
- 4. The options vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.

/s/ Steve Elms, by Brian Lenz as Attorney-in-fact

02/28/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.